CD4 and Sepsis: GM-CSF treatment has been proven to significantly reduce the levels of bone marrow-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) in sepsis patients, enhance the function of CD4+ T cells, improve the immune status, and thereby reduce the risk of infection and improve clinical prognosis.